Patients with type 2 diabetes (T2D) have above normal levels of glucose (sugar) in their blood. T2D is primarily diagnosed in adults however, there has been a significant increase of T2D in children and teens in recent years. Unlike adults, the children and teen population with T2D have fewer glucose-lowering treatment options that are regulatory approved. This study is investigating if a new medicine, called tirzepatide, is safe and effective for people with T2D between the ages of 10 and 18 years.

EP395 is a macrolide with anti-inflammatory and barrier protective properties, but without antibacterial effects. It is being developed as a treatment for COPD, to reduce exacerbations. The proposed study will assess the safety and tolerability of 3 months treatment in patients with COPD. The study will also assess the anti-inflammatory effects of EP395 in sputum. Exploratory endpoints will also be included with the aim to further understand mechanistic activity of EP395.

This trial will evaluate the efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or ianalumab given every 12 weeks (q12w) compared to placebo, in combination with SoC, in adult participants with active LN (ISN/RPS class III, IV active glomerulonephritis with or without co-existing class V features, or pure class V membranous). using the 2003 International Society for Nephrology (ISN)/Renal Pathology Society (RPS) criteria).

The study seeks to determine whether a new method, called the Glyconics-SX system, can detect type 2 diabetes from the amount of glycated (sugar-coated) nail protein called keratin by shining a light into an individual's middle fingernail. This study is now looking for adults aged 18 or over, with and without type 2 diabetes to take part.

The purpose of this study is to characterise the distribution of lipoprotein(a) (Lp(a)) levels among participants with a history of Atherosclerotic Cardiovascular Diseases (ASCVD) as defined by their medical history and is 2-fold:
- Evaluate the distribution of Lp(a) value in the overall participants with a documented history of ASCVD
- Evaluate the distribution of Lp(a) value in participants with a documented history of ASCVD by demographics and regions.

This is a multicentre, single-arm, phase 3b study designed to evaluate efficacy and safety of reducing daily oral corticosteroid use after initiation of 210 mg dose of Tezepelumab administered subcutaneously in patients with severe asthma receiving high-dose inhaled corticosteroid plus long-acting ß2 agonist and oral corticosteroids with or without additional asthma controller medications.

The purpose of this clinical research study is to evaluate the efficacy, safety and tolerability of the study medicine, volixibat, in patients with Intrahepatic cholestasis of pregnancy (ICP) and elevated serum bile acid concentrations.

The primary objective of the study is to evaluate the efficacy of dupilumab on the annualized rate of exacerbations in participants with Allergic Bronchopulmonary Aspergillosis (ABPA).

HbA1c levels are commonly measured in people with diabetes as they reflect the amount of sugar in the blood. This study aims to help us understand the relationship between HbA1c and average glucose, in a wide range of people with type 1 and type 2 diabetes. It involves wearing glucose sensors and regular blood tests for six months. 

This is an interventional, randomized, parallel group, treatment, Phase 3b/4, double blind, 2-arm study to assess the effect of dupilumab compared to standard of care therapy on preventing or slowing the rate of lung function decline in adult patients with uncontrolled moderate to severe asthma. The estimated duration is 4±1 weeks of screening and run-in period, followed by a 3-year double blinded treatment period. There will be a post-treatment follow-up (FU) period up to 12 weeks.